Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 8/20 | 0.41 |
| ▸ | FABP3 | P05413 | 4/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.41 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822276 | 0.94 | ADORA1 (0.46) | ADORA1FABP4FABP3FABP5FABP1 | |
| SCHEMBL6821916 | 0.91 | ADORA1 (0.42) | ADORA1FABP4FABP3FABP5FABP1 | |
| SCHEMBL6822503 | 0.90 | ADORA1 (0.41) | ADORA1 | |
| SCHEMBL6821896 | 0.90 | SMN1; SMN2 (0.43) | ADORA1HTT | |
| SCHEMBL6822034 | 0.90 | NPC1 (0.42) | ADORA1FABP4FABP3FABP5FABP1 | |
| SCHEMBL6822058 | 0.90 | ADORA1 (0.42) | ADORA1CMKLR1 | |
| SCHEMBL6821443 | 0.89 | LMNA (0.43) | ADORA1CMKLR1 | |
| SCHEMBL6818735 | 0.88 | ALDH1A1 (0.42) | ADORA1HTT | |
| SCHEMBL6818748 | 0.88 | ADORA1 (0.40) | ADORA1MAPK1HTT | |
| SCHEMBL6822546 | 0.88 | ADORA1 (0.41) | ADORA1CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885FABP4 4837/4885FABP3 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.